Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Obstetrics & Gynecology 1989;74:934-943
© 1989 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MORLEY, G. W.
Right arrow Articles by ROBERTS, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MORLEY, G. W.
Right arrow Articles by ROBERTS, J. A.

Pelvic Exenteration, University of Michigan: 100 Patients at 5 Years

GEORGE W. MORLEY, MD, MICHAEL P. HOPKINS, MD, S MARTIN LINDENAUER, MD and JAMES A. ROBERTS, MD

From the Department of Obstetrics and Gynecology, University of Michigan Medical Center, Ann Arbor, Michigan

Abstract

One hundred patients undergoing pelvic exenteration (total 69, anterior 13, posterior 18) at the University of Michigan Medical Center from 1964-1984 are reported. AH patients were followed for at least 5 years or until time of death. The overall cumulative survival was 66% at 3 years and 61% at 5 years. The age of the patients ranged from 21-74 years (median 53). The type of pelvic neoplasm included squamous cell of the cervix, 57; adenocarcinoma of the cervix, nine; squamous cell carcinoma of the vulva, 12; squamous cell carcinoma of the vagina, eight; vaginal sarcoma, four; adenocarcinoma of the vagina, one; adenocarcinoma of the endometrium, four; uterine sarcoma, four; and adenocarcinoma of the ovary, one. The cumulative 5-year survival was significantly related to the presence of metastatic disease to the regional lymph nodes (8% 3-year and 0% 5-year survival), time interval from primary diagnosis to exenteration (within 1 year 44%, 1-10 years 60%, and over 10 years 95%), and cell type (squamous cell 68%, sarcoma 62%, and adenocarcinoma 26%). Patients with squamous cell carcinoma of the cervix (N =7) had a cumulative 5-year survival of 73%, compared with nine patients with adenocarcinoma of the cervix, who had a 22% 5-year survival. No significant difference in survival existed for the type of exenteration, original stage of squamous cell cervical carcinoma, size of recurrent squamous cell lesion, or age of the patient. Early or late complications occurred in 49 patients. Two patients died in the postoperative period. Small-bowel obstruction was the most common complication seen in this series.




This article has been cited by other articles:


Home page
Ann. Surg. Oncol.Home page
T. M. Pawlik, J. M. Skibber, and M. A. Rodriguez-Bigas
Pelvic Exenteration for Advanced Pelvic Malignancies
Ann. Surg. Oncol., May 1, 2006; 13(5): 612 - 623.
[Full Text] [PDF]


Home page
Obstet GynecolHome page
A. K. Sood, B. C. Cooper, J. I. Sorosky, P. T. Ramirez, and C. Levenback
Novel Modification of the Vertical Rectus Abdominis Myocutaneous Flap for Neovagina Creation
Obstet. Gynecol., March 1, 2005; 105(3): 514 - 518.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
S. A. Cannistra and J. M. Niloff
Cancer of the Uterine Cervix
N. Engl. J. Med., April 18, 1996; 334(16): 1030 - 1037.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the American College of Obstetricians and Gynecologists.